Citations (44)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Pan Liu, Zhengdong Zhang, Jinwu Wang, Xiao Zhang, Xiaoping Yu & Yao Li. (2021) Empagliflozin protects diabetic pancreatic tissue from damage by inhibiting the activation of the NLRP3/caspase-1/GSDMD pathway in pancreatic β cells: in vitro and in vivo studies. Bioengineered 12:2, pages 9356-9366.
Read now
Read now
Carol H. Wysham, Dominic Pilon, Mike Ingham, Marie-Hélène Lafeuille, Bruno Emond, Rhiannon Kamstra, Michael Pfeifer & Patrick Lefebvre. (2018) Quality goal attainment and maintenance in patients with type II diabetes mellitus initiated on canagliflozin or a glucagon-like peptide-1 receptor agonist in an actual practice setting. Current Medical Research and Opinion 34:6, pages 1125-1133.
Read now
Read now
Abhiroop Chakravarty, Mohini Rastogi, Praveen Dhankhar & Kelly F. Bell. (2018) Comparison of costs and outcomes of dapagliflozin with other glucose-lowering therapy classes added to metformin using a short-term cost-effectiveness model in the US setting. Journal of Medical Economics 21:5, pages 497-509.
Read now
Read now
Yoshio Nagai, Akio Ohta, Yukiyoshi Sada, Hiroyuki Kato & Yasushi Tanaka. (2017) Effect of 24-week treatment with ipragliflozin on proinsulin/C-peptide ratio in Japanese patients with type 2 diabetes. Expert Opinion on Pharmacotherapy 18:1, pages 13-17.
Read now
Read now
Articles from other publishers (40)
Anjay Rastogi & James L. JanuzziJr.Jr.. (2023) Pleiotropic Effects of Sodium-Glucose Cotransporter-2 Inhibitors in Cardiovascular Disease and Chronic Kidney Disease. Journal of Clinical Medicine 12:8, pages 2824.
Crossref
Crossref
Pengcheng Li, Jiaqi Tan, Mi Xiao, Xu Cai, Hongkun Xue & Hansong Yu. (2023) Bioactive Substances and Biological Functions in Malus hupehensis: A Review. Molecules 28:2, pages 658.
Crossref
Crossref
Aisha Sheikh, Bhagwan Das, Saadia Sattar & Najmul Islam. (2022) Safety of sodium-glucose cotransporter 2 inhibitors (SGLT2i) during the month of Ramadan in patients with type 2 diabetes mellitus in Pakistani population—an observational study from a tertiary care center in Karachi. Endocrine 80:1, pages 64-70.
Crossref
Crossref
Xiaoya Sun & Guohong Wang. (2022) Renal outcomes with sodium-glucose cotransporters 2 inhibitors. Frontiers in Endocrinology 13.
Crossref
Crossref
Serge A. Jabbour, Nasrien E. Ibrahim & Christos P. Argyropoulos. (2022) Physicians’ Considerations and Practice Recommendations Regarding the Use of Sodium-Glucose Cotransporter-2 Inhibitors. Journal of Clinical Medicine 11:20, pages 6051.
Crossref
Crossref
Rahul Mishra, Ghada Elshimy, Lakshmi Kannan & Rishi Raj. (2022) Sodium–glucose cotransporter 2 inhibitor-associated severe epididymo-orchitis. BMJ Case Reports 15:7, pages e250942.
Crossref
Crossref
Chen Ding, Yaxin Tang, Wenqiang Zhu, Piaopiao Huang, Pingan Lian, Juanli Ran & Xiansheng Huang. (2022) Sodium-glucose cotransporter protein-2 inhibitors and glucagon-like peptide-1 receptor agonists versus thiazolidinediones for non-alcoholic fatty liver disease: A network meta-analysis. Acta Diabetologica 59:4, pages 519-533.
Crossref
Crossref
Meili Cai, Xiaowen Shao, Feng Xing, Yuqin Zhang, Xinyu Gao, Qiongjing Zeng, Diliqingna Dilimulati, Shen Qu & Manna Zhang. (2021) Efficacy of canagliflozin versus metformin in women with polycystic ovary syndrome: A randomized, open‐label, noninferiority trial. Diabetes, Obesity and Metabolism 24:2, pages 312-320.
Crossref
Crossref
Min Shi, Chao Wang, Jun Ji, Qu Cai, Qianfu Zhao, Wenqi Xi & Jun Zhang. (2022) CRISPR/Cas9-mediated knockout of SGLT1 inhibits proliferation and alters metabolism of gastric cancer cells. Cellular Signalling 90, pages 110192.
Crossref
Crossref
Alicia Swee Yan Yip, Shariel Leong, Yao Hao Teo, Yao Neng Teo, Nicholas L. X. Syn, Ray Meng See, Caitlin Fern Wee, Elliot Yeung Chong, Chi-Hang Lee, Mark Y. Chan, Tiong-Cheng Yeo, Raymond C. C. Wong, Ping Chai & Ching-Hui Sia. (2022) Effect of sodium-glucose cotransporter-2 (SGLT2) inhibitors on serum urate levels in patients with and without diabetes: a systematic review and meta-regression of 43 randomized controlled trials. Therapeutic Advances in Chronic Disease 13, pages 204062232210835.
Crossref
Crossref
Caiyun Zheng, Meimei Lin, Yan Chen, Haiting Xu, Lingqun Yan & Hengfen Dai. (2021) Effects of sodium‐glucose cotransporter type 2 inhibitors on cardiovascular, renal, and safety outcomes in patients with cardiovascular disease: a meta‐analysis of randomized controlled trials. Cardiovascular Diabetology 20:1.
Crossref
Crossref
HoJin Shin, Sebastian Schneeweiss, Robert J. Glynn & Elisabetta Patorno. (2021) Trends in First-Line Glucose-Lowering Drug Use in Adults With Type 2 Diabetes in Light of Emerging Evidence for SGLT-2i and GLP-1RA. Diabetes Care 44:8, pages 1774-1782.
Crossref
Crossref
Abdullah M. Alguwaihes. (2021) Safety of Dapagliflozin in Patients with Type 2 Diabetes Mellitus in Saudi Arabia: A Post Authorization Safety Study. Diabetes Therapy 12:7, pages 1979-1992.
Crossref
Crossref
Bo Ahrén & Giovanni Pacini. (2020) Glucose effectiveness: Lessons from studies on insulin‐independent glucose clearance in mice. Journal of Diabetes Investigation 12:5, pages 675-685.
Crossref
Crossref
Shihao Hu, Yuzhi Lu, Andrea Tura, Giovanni Pacini & David Z. D’Argenio. (2021) An Analysis of Glucose Effectiveness in Subjects With or Without Type 2 Diabetes via Hierarchical Modeling. Frontiers in Endocrinology 12.
Crossref
Crossref
Annette Schürmann & Hans-Georg Joost. 2021. Encyclopedia of Molecular Pharmacology. Encyclopedia of Molecular Pharmacology
530
535
.
Annette Schürmann & Hans-Georg Joost. 2020. Encyclopedia of Molecular Pharmacology. Encyclopedia of Molecular Pharmacology
1
6
.
Pieter Gillard, Oliver Schnell & Per-Henrik Groop. (2020) The nephrological perspective on SGLT-2 inhibitors in type 1 diabetes. Diabetes Research and Clinical Practice 170, pages 108462.
Crossref
Crossref
Oliver Schnell, Paul Valensi, Eberhard Standl & Antonio Ceriello. (2020) Comparison of mechanisms and transferability of outcomes of SGLT2 inhibition between type 1 and type 2 diabetes. Endocrinology, Diabetes & Metabolism 3:3.
Crossref
Crossref
Rory J. McCrimmon, Andrei-Mircea Catarig, Juan P. Frias, Nanna L. Lausvig, Carel W. le Roux, Desirée Thielke & Ildiko Lingvay. (2020) Effects of once-weekly semaglutide vs once-daily canagliflozin on body composition in type 2 diabetes: a substudy of the SUSTAIN 8 randomised controlled clinical trial. Diabetologia 63:3, pages 473-485.
Crossref
Crossref
Micaela Morettini, Carlo CastriotaChristian GöblAlexandra Kautzky-WillerGiovanni PaciniLaura BurattiniAndrea Tura. (2020) Glucose Effectiveness from Short Insulin-Modified IVGTT and Its Application to the Study of Women with Previous Gestational Diabetes Mellitus. Diabetes & Metabolism Journal 44:2, pages 286.
Crossref
Crossref
Micaela Morettini, Ludovica Ilari, Christian Göbl, Alexandra Kautzky-Willer, Andrea Tura, Giovanni Pacini & Laura Burattini. 2020. XV Mediterranean Conference on Medical and Biological Engineering and Computing – MEDICON 2019. XV Mediterranean Conference on Medical and Biological Engineering and Computing – MEDICON 2019
500
507
.
Kaoru SugimotoIchiro AbeMidori MinezakiYuichi TakashiKentaro OchiHideyuki FujiiHanako OhishiYuka YamaoTadachika KudoKenji OheMakiko AbeYasushi OhnishiTomohiro ShinagawaShigeaki MukoubaraKunihisa Kobayashi. (2019) Investigation of efficacy and safety of low-dose sodium glucose transporter 2 inhibitors and differences between two agents, canagliflozin and ipragliflozin, in patients with type 2 diabetes mellitus. Drug Discoveries & Therapeutics 13:6, pages 322-327.
Crossref
Crossref
Kazunori Utsunomiya, Masayuki Senda, Seigo Kakiuchi, Hiroyuki Kameda, Masahiro Tamura, Yuji Kurihara, Ryoji Gunji, Shoko Fujii, Hisataka Fujiwara & Kohei Kaku. (2019) Safety and efficacy of tofogliflozin in Japanese patients with type 2 diabetes mellitus in real‐world clinical practice: Results of 3‐month interim analysis of a long‐term post‐marketing surveillance study (J‐STEP/LT). Journal of Diabetes Investigation 10:5, pages 1272-1283.
Crossref
Crossref
William Hinton, Michael D. Feher, Neil Munro & Simon de Lusignan. (2019) How Generalizable Are Cardiovascular Outcome Trials of Sodium-Glucose Co-Transporter-2 Inhibitors? A National Database Study: Study Protocol. Diabetes Therapy 10:3, pages 1163-1170.
Crossref
Crossref
Vincent Woo, Alan Bell, Maureen Clement, Luis Noronha, Michael A. Tsoukas, Fernando Camacho, Shana Traina, Natasha Georgijev, Matthew D. Culham, Jennifer B. Rose, Wally Rapattoni & Harpreet S. Bajaj. (2018) CANadian CAnagliflozin REgistry: Effectiveness and safety of canagliflozin in the treatment of type 2 diabetes mellitus in Canadian clinical practice. Diabetes, Obesity and Metabolism 21:3, pages 691-699.
Crossref
Crossref
Ahmad A. Jiman, Kavaljit H. Chhabra, Alfor G. Lewis, Paul S. Cederna, Randy J. Seeley, Malcolm J. Low & Tim M. Bruns. (2018) Electrical stimulation of renal nerves for modulating urine glucose excretion in rats. Bioelectronic Medicine 4:1.
Crossref
Crossref
Micaela Morettini, Francesco Di Nardo, Laura Burattini, Sandro Fioretti, Christian Göbl, Alexandra Kautzky-Willer, Giovanni Pacini & Andrea Tura. (2018) Assessment of glucose effectiveness from short IVGTT in individuals with different degrees of glucose tolerance. Acta Diabetologica 55:10, pages 1011-1018.
Crossref
Crossref
Karim G. Kheniser & Sangeeta R. Kashyap. (2018) Diabetes management before, during, and after bariatric and metabolic surgery. Journal of Diabetes and its Complications 32:9, pages 870-875.
Crossref
Crossref
Shin‐ichi Harashima, Nobuya Inagaki, Kazuoki Kondo, Nobuko Maruyama, Makiko Otsuka, Yutaka Kawaguchi & Yumi Watanabe. (2018) Efficacy and safety of canagliflozin as add‐on therapy to a glucagon‐like peptide‐1 receptor agonist in Japanese patients with type 2 diabetes mellitus: A 52‐week, open‐label, phase IV study. Diabetes, Obesity and Metabolism 20:7, pages 1770-1775.
Crossref
Crossref
Carol H. Wysham, Dominic Pilon, Mike Ingham, Marie -Hélène Lafeuille, Bruno Emond, Rhiannon Kamstra, Michael Pfeifer & Patrick Lefebvre. (2018) Hba1C Control And Cost-Effectiveness in Patients With Type 2 Diabetes Mellitus Initiated On Canagliflozin or A Glucagon-Like Peptide 1 Receptor Agonist in A Real-World Setting. Endocrine Practice 24:3, pages 273-288.
Crossref
Crossref
G. Sesti, R. Antonelli Incalzi, E. Bonora, A. Consoli, A. Giaccari, S. Maggi, G. Paolisso, F. Purrello, G. Vendemiale & N. Ferrara. (2018) Management of diabetes in older adults. Nutrition, Metabolism and Cardiovascular Diseases 28:3, pages 206-218.
Crossref
Crossref
Takashi Kadowaki, Nobuya Inagaki, Kazuoki Kondo, Kenichi Nishimura, Genki Kaneko, Nobuko Maruyama, Nobuhiro Nakanishi, Maki Gouda, Hiroaki Iijima & Yumi Watanabe. (2017) Efficacy and safety of teneligliptin added to canagliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: A multicentre, randomized, double‐blind, placebo‐controlled, parallel‐group comparative study. Diabetes, Obesity and Metabolism 20:2, pages 453-457.
Crossref
Crossref
Carol H. Wysham, Patrick Lefebvre, Dominic Pilon, Mike Ingham, Marie-Hélène Lafeuille, Bruno Emond, Rhiannon Kamstra, Wing Chow, Michael Pfeifer & Mei Sheng Duh. (2017) Quality measure and weight loss assessment in patients with type 2 diabetes mellitus treated with canagliflozin or dipeptidyl peptidase-4 inhibitors. BMC Endocrine Disorders 17:1.
Crossref
Crossref
Jaime Davidson, Sanjay Kalra, Vikram Singh, Mayuresh Fegade, Gursimran Singh & Amey Mane. (2017) Resolving the KgA1c paradox in the management of type 2 diabetes mellitus. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 11, pages S159-S168.
Crossref
Crossref
Yasuo Terauchi, Masahiro Tamura, Masayuki Senda, Ryoji Gunji & Kohei Kaku. (2017) Efficacy and safety of tofogliflozin in Japanese patients with type 2 diabetes mellitus with inadequate glycaemic control on insulin therapy (J-STEP/INS): Results of a 16-week randomized, double-blind, placebo-controlled multicentre trial. Diabetes, Obesity and Metabolism 19:10, pages 1397-1407.
Crossref
Crossref
Jacqueline Kai Chin Chuah & Daniele Zink. (2017) Stem cell-derived kidney cells and organoids: Recent breakthroughs and emerging applications. Biotechnology Advances 35:2, pages 150-167.
Crossref
Crossref
Jiyoung Park & Hyeung-Jin Jang. (2017) Anti-diabetic effects of natural products an overview of therapeutic strategies. Molecular & Cellular Toxicology 13:1, pages 1-20.
Crossref
Crossref
Hiroyuki Tanaka, Kazuhiko Takano, Hiroaki Iijima, Hajime Kubo, Nobuko Maruyama, Toshio Hashimoto, Kenji Arakawa, Masanori Togo, Nobuya Inagaki & Kohei Kaku. (2016) Factors Affecting Canagliflozin-Induced Transient Urine Volume Increase in Patients with Type 2 Diabetes Mellitus. Advances in Therapy 34:2, pages 436-451.
Crossref
Crossref
Bhavana Sosale, Aravind Sosale & Arpandev Bhattacharyya. (2016) Clinical Effectiveness and Impact on Insulin Therapy Cost After Addition of Dapagliflozin to Patients with Uncontrolled Type 2 Diabetes. Diabetes Therapy 7:4, pages 765-776.
Crossref
Crossref